Plasma Protein Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||922053|
|出版日期||內容資訊||英文 113 Pages
|全球血漿蛋白質治療藥市場:成長，趨勢，及預測 Plasma Protein Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 113 Pages||
The plasma protein therapeutics market studied was projected to grow with a CAGR of nearly 5.3% over the forecast period. The major factor attributing to the growth of the market is the increasing prevalence of immune deficiency disorders, autoimmune disorders, neurological and bleeding disorders. In addition, the rise in geriatric population who are more prone to neurological disorders. Furthermore, the growing investments in research and development programs by the biotechnology and pharmaceutical companies is boosting the market growth. The current happening research and development in the plasma protein segment are anticipated to drive its use through several applications. The expanding use of therapeutic protein drugs in the treatment of a broad range of clinical symptoms is expected to generate several growth opportunities for this market in forthcoming years. However, stringent regulations for the handling of plasma protein products, and lack of reimbursement policies are the drawbacks that hinder the market growth.
As per the scope of the report plasma protein therapy, treats distinct medical conditions, restoring missing or inadequate proteins found in plasma, to allow their receivers to lead healthier and more productive lives. The patients that rely upon plasma protein therapies generally require regular infusions for the duration of their lives. This report is segmented by product, by application, and by geography.
Albumin segment is expected to be the Fastest-Growing Segment over the Forecast Period
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall plasma protein therapeutics market, throughout the forecast period. The market growth is due to factors like increasing prevalence and incidence of autoimmune and neurological diseases. Increasing the geriatric population in this region also increases the patient pool like the old age people are more prone to neurological diseases. Furthermore, beneficial government initiatives, escalating awareness levels among the blood donors, existence of advanced protein fractioning procedures, greater per capita income in the developed countries, increase in the number of research partnerships are some of the drivers expected to increase the market growth in the region.
The plasma protein therapeutics market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market Takeda Pharmaceutical Company Ltd, Octapharma USA Inc., Grifols, S.A., CSL Behring, Biotest AG, Baxter, and China Biologic Products Holdings, Inc.